Kazia Therapeutics Ltd is an Australian biotechnology company focused on oncology drug development. Its lead product candidate is Paxalisib (formerly GDC-0084), a small molecule inhibitor of the PI3K/Akt/mTOR pathway for cancer treatment. Its second candidate is EVT801, a small molecule selective inhibitor of VEGFR3. The company has not yet commercialized any products and finances operations primarily through equity issuances, Australian government R&D grants, and licensing arrangements.
No 10-K filings indexed.
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2006-11-07 | 2006-11-06 | 0001075880-06-000066 | EDGAR | 14K words |
678 total filings indexed. 677 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001075880 |
| Ticker | KZIA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | C3 |
| Website | https://www.kaziatherapeutics.com |
| Listed | 1999-01-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KZIA (~200 tokens, structured JSON with cryptographic provenance)